Bayer

Valuation Analysis

About the Company

Bayer en bref

Bayer (BAYN.DE) is currently trading at 37,15 € with a market capitalization of 31,9 Md €. The 52-week range spans from 24,80 € to 49,78 €; the current price is 25.4% below the yearly high. Year-over-year revenue growth stands at -2.4%.

💰 Dividende

Bayer pays an annual dividend of 0,11 € per share, representing a yield of 0.3%. The payout ratio stands at 163.27%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

19 analystes évaluent Bayer (BAYN.DE) au consensus : Acheter. L'objectif de cours moyen est de 49,50 €, soit un potentiel de +33.24% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 30,00 € à 60,00 €.

Bayer : la thèse d'investissement en détail

Bayer (BAYN.DE) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 112.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 59.92% gross margin and 26.32% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 33.24% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -2.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

At a PEG of 4.65, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 6.67x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The analyst consensus price target implies 33.24% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Bayer?

Compare top-rated brokers — low fees, trusted providers, fully regulated.